MX2012009217A - Pellets farmaceuticos administrables por via oral de factor de crecimiento epidermico. - Google Patents
Pellets farmaceuticos administrables por via oral de factor de crecimiento epidermico.Info
- Publication number
- MX2012009217A MX2012009217A MX2012009217A MX2012009217A MX2012009217A MX 2012009217 A MX2012009217 A MX 2012009217A MX 2012009217 A MX2012009217 A MX 2012009217A MX 2012009217 A MX2012009217 A MX 2012009217A MX 2012009217 A MX2012009217 A MX 2012009217A
- Authority
- MX
- Mexico
- Prior art keywords
- growth factor
- epidermal growth
- orally administrable
- administrable pharmaceutical
- pharmaceutical pellet
- Prior art date
Links
- 239000008188 pellet Substances 0.000 title abstract 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 title abstract 2
- 101800003838 Epidermal growth factor Proteins 0.000 title abstract 2
- 229940116977 epidermal growth factor Drugs 0.000 title abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención comprende un pellet de factor de crecimiento epidérmico y metionina o K2S2O7, una cápsula que comprende estos pellets, procesos para sus preparaciones y su uso para el tratamiento de la colitis ulcerosa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382033A EP2364690A1 (en) | 2010-02-12 | 2010-02-12 | Orally administrable pharmaceutical pellet of epidermal growth factor |
| PCT/EP2011/051918 WO2011098499A1 (en) | 2010-02-12 | 2011-02-10 | Orally administrable pharmaceutical pellet of epidermal growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012009217A true MX2012009217A (es) | 2012-11-23 |
Family
ID=42355395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009217A MX2012009217A (es) | 2010-02-12 | 2011-02-10 | Pellets farmaceuticos administrables por via oral de factor de crecimiento epidermico. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9205130B2 (es) |
| EP (2) | EP2364690A1 (es) |
| JP (1) | JP5778184B2 (es) |
| KR (1) | KR101745750B1 (es) |
| CN (1) | CN102753146B (es) |
| AR (1) | AR080144A1 (es) |
| AU (1) | AU2011214421B8 (es) |
| BR (1) | BR112012020223B8 (es) |
| CA (1) | CA2789055C (es) |
| DK (1) | DK2533758T3 (es) |
| ES (1) | ES2537704T3 (es) |
| HR (1) | HRP20150643T1 (es) |
| HU (1) | HUE024986T2 (es) |
| MX (1) | MX2012009217A (es) |
| PL (1) | PL2533758T3 (es) |
| PT (1) | PT2533758E (es) |
| RS (1) | RS54098B1 (es) |
| RU (1) | RU2540503C2 (es) |
| SI (1) | SI2533758T1 (es) |
| SM (1) | SMT201500158B (es) |
| WO (1) | WO2011098499A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102432737B (zh) * | 2011-09-07 | 2015-02-25 | 张绍国 | 一种缓释肠溶丙烯酸树脂乳胶液及其制法 |
| WO2014159609A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
| DK3482771T3 (da) * | 2013-03-14 | 2023-03-20 | Nestle Sa | Fremstilling af jordnøddeformuleringer til oral desensibilisering |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| JP2022514645A (ja) | 2018-12-20 | 2022-02-14 | アイミューン セラピューティクス，インコーポレイテッド | ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール |
| JP7574222B2 (ja) | 2019-05-10 | 2024-10-28 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | ピーナツアレルギー患者の生活の質を改善するための方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62149622A (ja) | 1985-12-24 | 1987-07-03 | Wakunaga Pharmaceut Co Ltd | 腸機能改善剤 |
| US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
| EP0262326B1 (de) * | 1986-08-07 | 1992-04-15 | Röhm Gmbh | Verfahren zur Herstellung eines redispergierbaren Kunststoffpulvers |
| JPH01246223A (ja) | 1988-03-28 | 1989-10-02 | Hitachi Chem Co Ltd | 潰瘍治療剤 |
| US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| WO1999030671A2 (en) * | 1997-12-15 | 1999-06-24 | Ron Eyal S | Aspected particles for oral delivery |
| US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| EP1517698B2 (en) | 2002-06-21 | 2017-12-06 | Novo Nordisk Health Care AG | STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES |
| JP2006503045A (ja) | 2002-09-16 | 2006-01-26 | ワイエス | ポリペプチド治療薬剤の経口投与のための遅延放出処方物と同薬剤の使用方法 |
| DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
| KR20070014114A (ko) | 2003-12-16 | 2007-01-31 | 유니버시티테크놀로지즈인터네셔날인코포레이티드 | 괴사성 장염의 치료 |
| WO2007095288A2 (en) * | 2006-02-13 | 2007-08-23 | Nektar Therapeutics | Methionine-containing protein or peptide compositions and methods of making and using |
| MXPA06013015A (es) * | 2006-11-09 | 2007-02-07 | Gastronomia Molecular S A | Nuevo proceso de elaboracion y estabilidad de un producto nutritivo de amaranto. |
| EP2334323A2 (en) * | 2008-09-10 | 2011-06-22 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
-
2010
- 2010-02-12 EP EP10382033A patent/EP2364690A1/en not_active Withdrawn
-
2011
- 2011-02-07 AR ARP110100394A patent/AR080144A1/es unknown
- 2011-02-10 PL PL11702645T patent/PL2533758T3/pl unknown
- 2011-02-10 BR BR112012020223A patent/BR112012020223B8/pt not_active IP Right Cessation
- 2011-02-10 PT PT117026450T patent/PT2533758E/pt unknown
- 2011-02-10 DK DK11702645.0T patent/DK2533758T3/da active
- 2011-02-10 HU HUE11702645A patent/HUE024986T2/en unknown
- 2011-02-10 WO PCT/EP2011/051918 patent/WO2011098499A1/en not_active Ceased
- 2011-02-10 RU RU2012139030/15A patent/RU2540503C2/ru active
- 2011-02-10 MX MX2012009217A patent/MX2012009217A/es active IP Right Grant
- 2011-02-10 CN CN201180008952.2A patent/CN102753146B/zh not_active Expired - Fee Related
- 2011-02-10 HR HRP20150643TT patent/HRP20150643T1/hr unknown
- 2011-02-10 US US13/578,211 patent/US9205130B2/en not_active Expired - Fee Related
- 2011-02-10 JP JP2012552388A patent/JP5778184B2/ja not_active Expired - Fee Related
- 2011-02-10 EP EP11702645.0A patent/EP2533758B1/en active Active
- 2011-02-10 CA CA2789055A patent/CA2789055C/en not_active Expired - Fee Related
- 2011-02-10 AU AU2011214421A patent/AU2011214421B8/en not_active Ceased
- 2011-02-10 RS RS20150439A patent/RS54098B1/sr unknown
- 2011-02-10 SI SI201130525T patent/SI2533758T1/sl unknown
- 2011-02-10 ES ES11702645.0T patent/ES2537704T3/es active Active
- 2011-02-10 KR KR1020127023348A patent/KR101745750B1/ko not_active Expired - Fee Related
-
2015
- 2015-07-03 SM SM201500158T patent/SMT201500158B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100528B (en) | Acid gas treatment | |
| SG10201903119QA (en) | Polypeptide vaccine | |
| DK3148532T3 (en) | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer | |
| MY182082A (en) | Biheteroaryl compounds and uses thereof | |
| ZA201208152B (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| PT3319620T (pt) | Lactobacillus paracasei para a produção de ácido linoleico conjugado, preparações nutricionais e farmacêuticas que o contêm e suas utilizações | |
| MX2012009217A (es) | Pellets farmaceuticos administrables por via oral de factor de crecimiento epidermico. | |
| IL249301A0 (en) | A reaction cell for a chemical reactor and a chemical reactor built from it | |
| WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
| SG10201608485XA (en) | (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel | |
| SG10201913983TA (en) | Ammonia oxidizing bacteria for treatment of acne | |
| IL250596A0 (en) | The composition for the treatment and prevention of urinary tract infections | |
| SG10201913394SA (en) | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| SG10201913380WA (en) | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| AU2017267955B2 (en) | Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia | |
| GB2554624B (en) | Process for the Treatment of Ashes and Digestates, Treated Ashes and Digestates thus obtained and uses thereof. | |
| EP2661434A4 (en) | NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| LT2640728T (lt) | Nauji monenzino dariniai, skirti pirmuonių sukeltų infekcijų gydymui | |
| SG10201913355RA (en) | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| ZA201804588B (en) | Pharmaceutical formulations for the treatment of diabetes | |
| EP3204486A4 (en) | Compact reactor for enzymatic treatment | |
| EP3137071A4 (en) | Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis | |
| WO2014056779A8 (de) | Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |